These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 38565898)
21. Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy. Ngougni Pokem P; Vanneste D; Schouwenburg S; Abdulla A; Gijsen M; Dhont E; Van der Linden D; Spriet I; De Cock P; Koch B; Van Bambeke F; Wijnant GJ Expert Opin Drug Metab Toxicol; 2024 Aug; 20(8):787-804. PubMed ID: 39078238 [TBL] [Abstract][Full Text] [Related]
22. β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value. Dilworth TJ; Schulz LT; Micek ST; Kollef MH; Rose WE Crit Care Explor; 2022 Jul; 4(7):e0726. PubMed ID: 35815181 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic aspects of beta-lactam antibiotic therapy in intensive care unit patients: A one-center experience with TDM. Sadilová K; Halačová M; Černý D Ceska Slov Farm; 2020; 69(1):17-23. PubMed ID: 32460506 [TBL] [Abstract][Full Text] [Related]
24. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France. Charmillon A; Novy E; Agrinier N; Leone M; Kimmoun A; Levy B; Demoré B; Dellamonica J; Pulcini C Clin Microbiol Infect; 2016 Jul; 22(7):625-31. PubMed ID: 27145210 [TBL] [Abstract][Full Text] [Related]
25. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226 [TBL] [Abstract][Full Text] [Related]
26. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal. Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492 [TBL] [Abstract][Full Text] [Related]
27. A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients. Abdulla A; Ewoldt TMJ; Purmer IM; Muller AE; Gommers D; Endeman H; Koch BCP Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):359-368. PubMed ID: 33463382 [TBL] [Abstract][Full Text] [Related]
28. Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill. Wessel RJ; Rivera CG; Ausman SE; Martin N; Braga SA; Hagy NT; Moreland-Head LN; Abu Saleh OM; Gajic O; Jannetto PJ; Barreto EF Int J Qual Health Care; 2024 Jul; 36(3):. PubMed ID: 38955670 [TBL] [Abstract][Full Text] [Related]
29. Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis. Gatti M; Cojutti PG; Pea F Crit Care; 2024 Apr; 28(1):123. PubMed ID: 38627763 [TBL] [Abstract][Full Text] [Related]
30. Comparison of extended versus intermittent infusion of antipseudomonal beta-lactams for the treatment of critically ill patients with respiratory infections: A systematic review and meta-analysis. Aboulatta L; Sugita H; Wakabayashi H; Noma H; Sasaki T Int J Infect Dis; 2020 Sep; 98():41-50. PubMed ID: 32535299 [TBL] [Abstract][Full Text] [Related]
31. Loading dose and efficacy of continuous or extended infusion of beta-lactams compared with intermittent administration in patients with critical illnesses: A subgroup meta-analysis and meta-regression analysis. Wu CC; Su YC; Wu KS; Wu TH; Yang CS J Clin Pharm Ther; 2021 Apr; 46(2):424-432. PubMed ID: 33135261 [TBL] [Abstract][Full Text] [Related]
32. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Sime FB; Udy AA; Roberts JA Curr Opin Pharmacol; 2015 Oct; 24():1-6. PubMed ID: 26119486 [TBL] [Abstract][Full Text] [Related]
33. Experience with Implementing a Beta-lactam Therapeutic Drug Monitoring Service in a Burn Intensive Care Unit: A Retrospective Chart Review. Alshaer M; Mazirka P; Burch G; Peloquin C; Drabick Z; Carson J J Burn Care Res; 2023 Jan; 44(1):121-128. PubMed ID: 35896122 [TBL] [Abstract][Full Text] [Related]
34. Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base. Abdul-Aziz MH; Portunato F; Roberts JA Curr Opin Infect Dis; 2020 Dec; 33(6):501-510. PubMed ID: 33009140 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome. Koch BCP; Muller AE; Hunfeld NGM; de Winter BCM; Ewoldt TMJ; Abdulla A; Endeman H Ther Drug Monit; 2022 Feb; 44(1):11-18. PubMed ID: 34772892 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections? Muller AE; Huttner B; Huttner A Drugs; 2018 Mar; 78(4):439-451. PubMed ID: 29476349 [TBL] [Abstract][Full Text] [Related]
37. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. Wong G; Brinkman A; Benefield RJ; Carlier M; De Waele JJ; El Helali N; Frey O; Harbarth S; Huttner A; McWhinney B; Misset B; Pea F; Preisenberger J; Roberts MS; Robertson TA; Roehr A; Sime FB; Taccone FS; Ungerer JP; Lipman J; Roberts JA J Antimicrob Chemother; 2014 May; 69(5):1416-23. PubMed ID: 24443514 [TBL] [Abstract][Full Text] [Related]
38. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study. Carrié C; Petit L; d'Houdain N; Sauvage N; Cottenceau V; Lafitte M; Foumenteze C; Hisz Q; Menu D; Legeron R; Breilh D; Sztark F Int J Antimicrob Agents; 2018 Mar; 51(3):443-449. PubMed ID: 29180280 [TBL] [Abstract][Full Text] [Related]
39. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Huttner A; Von Dach E; Renzoni A; Huttner BD; Affaticati M; Pagani L; Daali Y; Pugin J; Karmime A; Fathi M; Lew D; Harbarth S Int J Antimicrob Agents; 2015 Apr; 45(4):385-92. PubMed ID: 25656151 [TBL] [Abstract][Full Text] [Related]
40. Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study. Ewoldt TMJ; Abdulla A; van den Broek P; Hunfeld N; Bahmany S; Muller AE; Gommers D; Polinder S; Endeman H; Spronk I; Koch BCP BMC Infect Dis; 2022 Jul; 22(1):611. PubMed ID: 35831793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]